
Opinion|Videos|May 6, 2024
Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO
Author(s)Marion Munk, MD, PhD
Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Demodex blepharitis: Closing the diagnostic gap to improve ocular surface health
2
Study examines accommodation after iris-fixated phakic IOL implantation
3
AI-predicted retinal function shows promise in geographic atrophy
4
European Dry Eye Society Congress 2026: real-world evidence on Artelac Complete in dry eye disease
5


























